Adamas Pharmaceuticals reported 29.73M in Selling and Administration Expenses for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Abbvie ABBV:US $ 2.98B 99M
Acadia Pharmaceuticals ACAD:US $ 81.67M 15.12M
Acorda Therapeutics ACOR:US $ 29.62M 2.74M
Adamas Pharmaceuticals ADMS:US 29.73M 579K
Aerie Pharmaceuticals AERI:US $ 34.66M 114K
Aptinyx Inc APTX:US $ 4.93M 142K
Biocryst Pharmaceuticals BCRX:US $ 34.99M 8.67M
Flexion Therapeutics FLXN:US $ 26.99M 423K
GlaxoSmithKline GSK:LN 2.5B 6M
Glaxosmithkline GSK:US 2.5B 6M
Gw Pharmaceuticals GWPH:US 101.05M 2.71M
Heron Therapeutics HRTX:US $ 34.99M 1.84M
Intra Cellular Therapies ITCI:US $ 70.5M 646.73K
Marinus Pharmaceuticals MRNS:US 9.45M 2.62M
Merk MRK:US $ 2.27B 9M
Neurocrine Biosciences NBIX:US $ 154.6M 11.4M
Novartis NOVN:VX 3.6B 109M
Omeros OMER:US $ 20.86M 699K
Prothena PRTA:US 11.96M 923K
Revance Therapeutics RVNC:US $ 51.12M 2.11M
Teva Pharmaceutical TEVA:IT 864M 32M
Zogenix ZGNX:US $ 39.56M 5.68M